معرفی
Lara Magni serves as a Guest Researcher in the Department of Biology at the Faculty of Science, University of Copenhagen, affiliated with the Genome Research and Molecular Bio Medicine division. Her contact details include email lara.magni@bio.ku.dk and phone +4535326756 at Universitetsparken 13, 2100 Copenhagen Ø. She completed her Ph.D. at the University of Copenhagen in 2022 with a thesis on ATP and P2X7 receptor mechanisms in pancreatic cancer.
Her research centers on pancreatic cancer pathogenesis, specifically investigating purinergic signaling pathways through the P2X7 receptor. Key interests include genetic polymorphisms affecting receptor function, ATP-mediated cellular signaling, IL-6/STAT3 inflammatory cascades, and therapeutic repurposing of proton pump inhibitors and tocilizumab. This work bridges molecular oncology, cancer genetics, and translational pharmacology to identify novel treatment targets.
Analysis of her six publications (2020-2024) reveals a cohesive research trajectory focused on P2X7 receptor dynamics in pancreatic cancer microenvironments. Her studies demonstrate how receptor variants influence cancer risk, how ATP signaling drives stellate cell activation, and how existing drugs may inhibit tumor progression through H+, K+-ATPase targeting. The work consistently integrates molecular, cellular, and clinical perspectives to advance therapeutic strategies.
No scientific awards were documented in available sources.
While specific grant funding and student advising details are unreported, her collaborative publications indicate active participation in I. Novak's research group. Co-author networks include Christensen N.M., Yu H., Tozzi M., and Novak I., suggesting interdisciplinary teamwork within the Department of Biology's cancer research cluster.
Dr. Magni operates within the Genome Research and Molecular Bio Medicine division, which focuses on molecular disease mechanisms and therapeutic development. Her current work examines P2X7 receptor polymorphisms and their clinical implications, with potential future directions in personalized pancreatic cancer treatments based on genetic profiling.
